Cargando…

Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging

Belantamab mafodotin (belamaf) is a novel antibody–drug conjugate developed for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Although the drug has demonstrated a good efficacy, corneal adverse events have been reported. In this prospective study, consecutive patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Mencucci, Rita, Cennamo, Michela, Alonzo, Ludovica, Senni, Carlotta, Vagge, Aldo, Ferro Desideri, Lorenzo, Scorcia, Vincenzo, Giannaccare, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147189/
https://www.ncbi.nlm.nih.gov/pubmed/35629012
http://dx.doi.org/10.3390/jcm11102884
_version_ 1784716746986356736
author Mencucci, Rita
Cennamo, Michela
Alonzo, Ludovica
Senni, Carlotta
Vagge, Aldo
Ferro Desideri, Lorenzo
Scorcia, Vincenzo
Giannaccare, Giuseppe
author_facet Mencucci, Rita
Cennamo, Michela
Alonzo, Ludovica
Senni, Carlotta
Vagge, Aldo
Ferro Desideri, Lorenzo
Scorcia, Vincenzo
Giannaccare, Giuseppe
author_sort Mencucci, Rita
collection PubMed
description Belantamab mafodotin (belamaf) is a novel antibody–drug conjugate developed for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Although the drug has demonstrated a good efficacy, corneal adverse events have been reported. In this prospective study, consecutive patients with RRMM who received belamaf infusions were included. The standard ophthalmological visit was implemented with anterior segment (AS)-optical coherence tomography (OCT) and in vivo confocal microscopy (IVCM). Five patients (three males, two females; mean age 66 ± 6.0 years) with MMRR and unremarkable ocular findings at baseline who received belamaf infusion were included. After a median time of 28 days from the first infusion, four of them developed corneal alterations with transient vision reduction to a variable extent. In particular, corneal deposits of microcyst-like epithelial changes (MECs) were detected centrally in one patient and peripherally in three patients. AS-OCT scans showed a bilateral heterogeneous increase in signal intensity, together with hyper-reflective lesions confined within the epithelium in all cases, except for one case in which they also involved the stroma. Corneal maps showed a transient increase in epithelial thickness in the first phase that was followed by a diffuse decrease in the subsequent phase. IVCM scans showed MECs as hyper-reflective opacities located at the level of corneal epithelium, largely intracellular. Multimodal corneal imaging may implement the current clinical scale, helping us to detect corneal abnormalities in patients under belamaf therapy. This workup provides useful data for monitoring over time corneal findings and for optimizing systemic therapy.
format Online
Article
Text
id pubmed-9147189
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91471892022-05-29 Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging Mencucci, Rita Cennamo, Michela Alonzo, Ludovica Senni, Carlotta Vagge, Aldo Ferro Desideri, Lorenzo Scorcia, Vincenzo Giannaccare, Giuseppe J Clin Med Article Belantamab mafodotin (belamaf) is a novel antibody–drug conjugate developed for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Although the drug has demonstrated a good efficacy, corneal adverse events have been reported. In this prospective study, consecutive patients with RRMM who received belamaf infusions were included. The standard ophthalmological visit was implemented with anterior segment (AS)-optical coherence tomography (OCT) and in vivo confocal microscopy (IVCM). Five patients (three males, two females; mean age 66 ± 6.0 years) with MMRR and unremarkable ocular findings at baseline who received belamaf infusion were included. After a median time of 28 days from the first infusion, four of them developed corneal alterations with transient vision reduction to a variable extent. In particular, corneal deposits of microcyst-like epithelial changes (MECs) were detected centrally in one patient and peripherally in three patients. AS-OCT scans showed a bilateral heterogeneous increase in signal intensity, together with hyper-reflective lesions confined within the epithelium in all cases, except for one case in which they also involved the stroma. Corneal maps showed a transient increase in epithelial thickness in the first phase that was followed by a diffuse decrease in the subsequent phase. IVCM scans showed MECs as hyper-reflective opacities located at the level of corneal epithelium, largely intracellular. Multimodal corneal imaging may implement the current clinical scale, helping us to detect corneal abnormalities in patients under belamaf therapy. This workup provides useful data for monitoring over time corneal findings and for optimizing systemic therapy. MDPI 2022-05-19 /pmc/articles/PMC9147189/ /pubmed/35629012 http://dx.doi.org/10.3390/jcm11102884 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mencucci, Rita
Cennamo, Michela
Alonzo, Ludovica
Senni, Carlotta
Vagge, Aldo
Ferro Desideri, Lorenzo
Scorcia, Vincenzo
Giannaccare, Giuseppe
Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging
title Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging
title_full Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging
title_fullStr Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging
title_full_unstemmed Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging
title_short Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging
title_sort corneal findings associated to belantamab-mafodotin (belamaf) use in a series of patients examined longitudinally by means of advanced corneal imaging
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147189/
https://www.ncbi.nlm.nih.gov/pubmed/35629012
http://dx.doi.org/10.3390/jcm11102884
work_keys_str_mv AT mencuccirita cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging
AT cennamomichela cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging
AT alonzoludovica cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging
AT sennicarlotta cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging
AT vaggealdo cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging
AT ferrodesiderilorenzo cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging
AT scorciavincenzo cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging
AT giannaccaregiuseppe cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging